A new collaboration has been announced to develop a next generation intracameral implant that fully degrades once the drug is depleted
Ripple Therapeutics has announced a collaboration and option-to-license agreement with AbbVie to develop RTC-620.
The fully biodegradable, sustained release drug delivery intracameral implant with repeat dosing capabilities is aimed to reduce intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).
“Ripple’s patented technology platform is based on a discovery that drugs can be engineered into controlled release pharmaceuticals without the use of polymers or excipients,” the company said in a news release.
“These proprietary prodrugs undergo surface erosion to give zero order release kinetics and are highly customisable to tailor both drug dose and duration.”
Ripple’s patented technology platform is based on a discovery that drugs can be engineered into controlled release pharmaceuticals without the use of polymers or excipients
According to Ripple, once the drug is depleted, the implant fully degrades without leaving behind harmful byproducts. This enables repeat dosing with minimal inflammation.
Ripple Therapeutics is a clinical stage ophthalmic therapeutics company with headquarters in Canada.
